VolitionRx (NYSE:VNRX) Receives New Coverage from Analysts at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX) in a report issued on Tuesday. The firm set a “sell” rating on the stock.

Separately, Benchmark reaffirmed a “hold” rating on shares of VolitionRx in a report on Friday, August 16th.

VolitionRx Trading Up 5.2 %

VNRX stock opened at $0.72 on Tuesday. VolitionRx has a 1-year low of $0.43 and a 1-year high of $1.23. The stock has a market cap of $59.29 million, a price-to-earnings ratio of -1.55 and a beta of 1.12. The company’s 50 day moving average is $0.65 and its 200 day moving average is $0.72.

VolitionRx (NYSE:VNRX) last announced its earnings results on Wednesday, August 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.01. The company had revenue of $0.40 million during the quarter, compared to analysts’ expectations of $0.34 million. As a group, sell-side analysts forecast that VolitionRx will post -0.31 EPS for the current fiscal year.

Insider Activity at VolitionRx

In related news, Director Guy Archibald Innes purchased 150,000 shares of the firm’s stock in a transaction on Tuesday, August 20th. The shares were acquired at an average cost of $0.67 per share, with a total value of $100,500.00. Following the purchase, the director now directly owns 406,683 shares of the company’s stock, valued at $272,477.61. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. 12.80% of the stock is currently owned by company insiders.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.